Company Overview
CorMedix Inc. operates as a biopharmaceutical company dedicated to the development and commercialization of therapeutic products designed to address life-threatening diseases and conditions within the United States market. The firm specifically focuses its efforts on creating solutions such as DefenCath, an antimicrobial catheter lock solution intended to reduce the incidence of catheter-related bloodstream infections, which highlights its specialization in high-impact healthcare innovations. This entity functions within the broader Healthcare sector and the specific Biotechnology industry, positioning it to leverage scientific advancements for medical applications that target critical patient needs. In terms of scale, the company holds a market capitalization of $522.52M and generates annual revenue of $311.71M while employing 191 individuals. These valuation and revenue figures indicate that CorMedix has established a significant presence in the biotech landscape, possessing a substantial asset base relative to its workforce size and demonstrating the ability to generate meaningful income from its product pipeline and operations.
Financial Health
The company reported a total revenue of $311.71M over the trailing twelve months, with a corresponding net income of $162.07M and an EBITDA figure of $174.89M. The substantial gap between the revenue figure and the net income reveals a highly efficient cost structure where operating expenses are managed effectively, allowing a significant portion of top-line sales to convert into bottom-line profit. Free cash flow stands at $108.51M, which provides the company with considerable financial flexibility to fund research and development initiatives, repay obligations, or pursue strategic acquisitions without relying heavily on external capital markets. The company maintains robust profitability metrics, with a gross margin of 92.9% indicating low cost of goods sold relative to sales, an operating margin of 53.9% reflecting efficient management of overhead and operational costs, and a profit margin of 52.3% demonstrating the ability to retain the majority of revenue as earnings. On the balance sheet, the company holds cash of $148.53M against total debt of $148.91M, resulting in a debt-to-equity ratio of 36.74%, which suggests a relatively leveraged position given the near-equalization of cash and debt assets. Liquidity is further supported by a current ratio of 2.11, indicating that the company possesses more than double the current assets necessary to cover its short-term liabilities, thereby ensuring strong short-term solvency. Return on equity is reported at 66.6% while return on assets stands at 21.2%, metrics that collectively reveal highly effective management in generating returns on the capital invested by shareholders and the broader asset base.
Valuation Assessment
The trailing twelve-month P/E ratio is 3.24, whereas the forward P/E is 9.05, implying that the market expects a significant expansion in earnings relative to current levels or that current earnings are suppressed by temporary factors. The price-to-book ratio is 1.29, which indicates that the market values the company at a slight premium over its net book value, suggesting confidence in the intrinsic value of its intangible assets and future cash-generating potential beyond tangible book equity. Alternative valuation metrics such as the price-to-sales ratio of 1.68 and the EV/EBITDA of 2.99 suggest that the stock is priced conservatively relative to its sales and earnings power, particularly when compared to the high margin profile. The stock has traded between a 52-week high of $17.43 and a 52-week low of $5.60, and without a specific current share price provided in the data, the range establishes the volatility envelope within which the asset has moved over the past year. The beta value is 1.42, which means the stock exhibits higher price volatility relative to the broader market, moving more aggressively than the benchmark index during periods of market fluctuation.
Growth & Income
Revenue growth for the trailing twelve months is 312.1%, while earnings growth is -28.3%, indicating that earnings are currently growing significantly slower than revenue, a dynamic often seen during periods of heavy investment or transitional accounting adjustments. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, meaning the organization chooses to reinvest all available earnings into growth initiatives, research, and operational expansion rather than distributing cash to shareholders. The disparity between the explosive revenue growth and the negative earnings growth highlights a phase of rapid scaling where top-line expansion outpaces bottom-line realization, potentially driven by the 312.1% increase in revenue against a backdrop of prior low or negative earnings bases. Overall, the growth and income profile is characterized by exceptional top-line expansion and zero dividend distribution, prioritizing capital allocation toward business development over immediate shareholder income returns.